GeneDx Holdings Corp.

NASDAQ:WGS

Medical - Healthcare Information Services

Healthcare
$51.96 +2.69%

+$1.52 today

Market cap
$1.56B
Beta
1.97
P/E (TTM)
-21.8
EPS (TTM)
-$2.65
52W Low $32.21High $170.87

Volume 1.71M

Average 1.28M

WGS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

GeneDx Holdings Corp.NASDAQ: WGS

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation dips below year-ago levels

Q2 FY2026 stock-based compensation of $6.34M fell 18.8% year over year, behind the +95.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 29.5% from the prior quarter. Over 3 fiscal years it compounded at -8.5% a year.

Context

  • Stock-based compensation amounted to 7.5% of revenue in FY2025, up 4.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -18.8% toward the trailing-twelve-month pace of +95.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.34M-29.5% QoQ
Last fiscal yearDec 2025
$32.16M+252.0% YoY
LTMJun 2026
$35.7M+95.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.8%——
1 year+252.0%——
3-year CAGR-8.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
32.16M USD
Year-over-year change
+252.0%
4-year CAGR
-38.1%

Stock-Based Compensation vs competitors

How WGS compares with its peers on the latest reported figures

  • WGS's LTM Jun 2026 stock-based compensation of $35.7M is the 2nd largest of the 9 companies compared; the peer median is $26.85M.
  • Its year-over-year change of +95.3% is the highest of 8, against a peer median of -8.9%.
  • Stock-based compensation amounts to 7.9% of revenue for WGS, versus a peer median of 7.7%.
WGS Competitors Peer median
Stock-Based Compensation for WGS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CSTLCastle Biosciences, Inc.LTM Mar 2026$44.49M -8.9%+8.1%13.1%
WGSGeneDx Holdings Corp.LTM Jun 2026$35.7M +95.3%-8.5%7.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$29.03M -33.3%+6.6%9.1%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$25.54M ——6.4%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.4M +50.7%-39.5%123.1%
MDXHMDxHealth S.A.FY2025$2.21M +28.2%+36.6%2.0%
Peer median (excluding WGS) $26.85M-8.9%+6.6%7.7%

Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(245.39M)(548.98M)(175.77M)(52.29M)(21.02M)
Depreciation & Amortization21.81M59.31M33.73M21.95M25.22M
Deferred Income Tax0(49.12M)(926K)(343K)0
Stock-Based Compensation219.42M41.98M(326K)9.14M32.16M
Change in Working Capital8.08M36.13M(38.24M)(24.75M)(15.6M)
Accounts Receivables5.54M5.53M10.26M(5.42M)(36.23M)
Inventory(10.62M)4.6M975K(2.59M)(3.44M)
Accounts Payables034.46M(46.95M)(20.46M)12.1M
Other Working Capital13.17M(8.46M)(2.53M)3.72M11.97M
Other Non-Cash Items(194.35M)141.53M1.38M17.79M12.51M
Operating Cash Flow(190.43M)(319.16M)(180.15M)(28.5M)33.28M
Capital Expenditures(20.79M)(14.32M)(5.71M)(5.49M)(19.02M)
Acquisitions (Net)0(127M)(8.11M)0(32.86M)
Purchases of Investments00(47.67M)(66.3M)(55.68M)
Sales of Investments0017.77M41.66M46.03M
Other Investing Activities(11.39M)0000
Investing Cash Flow(20.79M)(141.33M)(43.73M)(30.13M)(61.52M)
Debt Repayment(13.47M)(3.29M)42.95M(3.23M)(3.66M)
Common Stock Issued442.68M197.66M143M46.5M51.69M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities64.51M2.95M285K891K0
Financing Cash Flow493.73M197.32M186.24M44.16M48.03M
Effect of Forex Changes00(87K)00
Net Change in Cash282.51M(263.17M)(37.72M)(14.47M)19.79M
Free Cash Flow(211.22M)(333.48M)(185.86M)(33.99M)14.26M

GeneDx Holdings Corp.

NASDAQ:WGS

Intrinsic Alpha fair value

Locked

Current Price

$51.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.